Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 11/20 | 0.58 |
| ▸ | HRH2 | P25021 | 9/20 | 0.58 |
| ▸ | HRH1 | P35367 | 9/20 | 0.58 |
| ▸ | MEN1 | O00255 | 6/20 | 0.55 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2335855 | 0.89 | HRH3 (0.68) | HRH3HRH2HRH1MEN1SIGMAR1 | |
| SCHEMBL1714467 | 0.84 | HRH3 (0.68) | HRH3HRH2HRH1MEN1SIGMAR1 | |
| SCHEMBL3560997 | 0.82 | HRH3 (0.66) | HRH3HRH2HRH1MEN1SIGMAR1 | |
| Water SCHEMBL2903086 | 0.82 | HRH3 (0.66) | HRH3HRH2HRH1MEN1SIGMAR1 | |
| SCHEMBL3562862 | 0.82 | HRH3 (0.62) | HRH3HRH2HRH1MEN1SIGMAR1 | |
| SCHEMBL1714617 | 0.81 | HRH3 (0.61) | HRH3HRH2HRH1MEN1SIGMAR1 | |
| SCHEMBL7328846 | 0.78 | HRH3 (0.61) | HRH3HRH2HRH1MEN1SIGMAR1 | |
| SCHEMBL2903095 | 0.78 | MAPT (0.51) | HRH3HRH2HRH1 | |
| SCHEMBL7959199 | 0.78 | ALDH1A1 (0.51) | HRH3HRH2HRH1 | |
| SCHEMBL3559203 | 0.77 | SIGMAR1 (0.56) | HRH3HRH2HRH1MEN1SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8536343-B2 | Arylamidine derivative, salt thereof and antifungal agent containing those | TOYAMA CHEMICAL CO., LTD. (JP) | 2013-09-17 | — | — | US | disclosed |
| US-8536343-B2 | Arylamidine derivative, salt thereof and antifungal agent containing those | TOYAMA CHEMICAL CO., LTD. (JP) | 2013-09-17 | — | — | US | disclosed |
| EP-1967190-B1 | NOVEL ARYLAMIDINE DERIVATIVE, SALT THEREOF AND ANTIFUNGAL AGENT CONTAINING THOSE | TOYAMA CHEMICAL CO LTD (JP) | 2010-08-04 | — | — | EP | disclosed |
| US-20100016602-A1 | NOVEL ARYLAMIDINE DERIVATIVE, SALT THEREOF AND ANTIFUNGAL AGENT CONTAINING THOSE | TOYAMA CHEMICAL CO., LTD. (JP) | 2010-01-21 | — | — | US | disclosed |
| EP-1967190-A1 | NOVEL ARYLAMIDINE DERIVATIVE, SALT THEREOF AND ANTIFUNGAL AGENT CONTAINING THOSE | TOYAMA CHEMICAL CO., LTD. (JP) | 2008-09-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016602-A1 | NOVEL ARYLAMIDINE DERIVATIVE, SALT THEREOF AND ANTIFUNGAL AGENT CONTAINING THOSE | ERG28, DPM1, NAT1 | HRH3 202/4885HRH2 803/4885HRH1 662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.